GlaxoSmithKline PLC (GSK)

[csearle]

I wonder why you can't have it if you are on supplemental oxygen. Any clues?

It may be because being on supplemental oxygen, in an intensive care setting, implies the patient is beyond the point where the drug can really help? C.

[csearle]

I also wonder why all these drugs' names end in 'mab'.

Monoclonal antibodies (MABs) are a type of targeted drug therapy. All MABs have names that include 'mab' at the end of their generic name. C.


https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/monoclonal-antibodies

[Bouleversee]

I wonder why you can't have it if you are on supplemental oxygen. Any clues?

It may be because being on supplemental oxygen, in an intensive care setting, implies the patient is beyond the point where the drug can really help? C.

Or not worth spending money or time on?

[csearle]

I wonder why you can't have it if you are on supplemental oxygen. Any clues?

It may be because being on supplemental oxygen, in an intensive care setting, implies the patient is beyond the point where the drug can really help? C.

Or not worth spending money or time on?

These people have to make pragmatic decisions daily. When the system is at full-tilt (or overloaded) I imagine they have to make life/death decisions that must be very difficult; and sometimes difficult to live with without some kind of mental strut to support their choices. C.

[csearle]

PS Often the drug companies had pretty-much hoodwinked the medical community into believing their drug is God's gift when it is actually not as effective as they try to make out it is. (I have experience from an insider.) C.

[Bouleversee]

It may be because being on supplemental oxygen, in an intensive care setting, implies the patient is beyond the point where the drug can really help? C.

Or not worth spending money or time on?

These people have to make pragmatic decisions daily. When the system is at full-tilt (or overloaded) I imagine they have to make life/death decisions that must be very difficult; and sometimes difficult to live with without some kind of mental strut to support their choices. C.

Yes, I understand that.

[idpickering]

GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company

New world-leader in Consumer Healthcare on track to list in 2022

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Sir Dave Lewis has been appointed as Non-Executive Chair Designate of the new Consumer Healthcare company which will result from the proposed demerger from GSK in 2022. His appointment will take effect from 1st January 2022.

As set out at GSK's Investor Update in June 2021, subject to approval from shareholders, the separation of Consumer Healthcare will be by way of a demerger in mid-2022 of at least 80% of GSK's holding to shareholders. The new resulting company is expected to attain a premium listing on the London Stock Exchange.

The new business is expected to be a world-leader in Consumer Health offering the prospect of superior, sustainable sales growth and a highly attractive financial profile for investors. Since 2014, through successful strategic portfolio changes, including integrations of the Novartis consumer healthcare portfolio in 2015 and the Pfizer portfolio in 2019, GSK Consumer Healthcare has been transformed into a highly valuable and focused global business generating annual sales of more than £10 billion. The business now has an exceptional portfolio of world-class, category-leading brands, together with global scale and new innovation capabilities, offering a differentiated proposition that combines trusted science and human understanding.

Sir Dave is a highly experienced and respected global business leader in consumer goods and retail. From 2014 to 2020 he was Group Chief Executive Officer of Tesco plc and prior to that was Global President, Personal Care at Unilever. He also has extensive experience as a Board Director, in both the UK and US, having served on the Boards of Sky plc, Tesco plc and currently PepsiCo.

https://www.investegate.co.uk/glaxosmit ... 00071185W/

[Dod101]

So this is Dave from Tesco (where I think he did get quite a good job) Executive Chairman which is a bit unusual so he will be a bit more hands on than the usual Chairman. That I think bodes well for the future of this company.

I did not realise that he had been knighted.

Dod

[idpickering]

ViiV Healthcare announces FDA approval of Apretude

ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

· Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition

· Approved in the US for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV, including men who have sex with men as well as women and transgender women who have sex with men

https://www.investegate.co.uk/glaxosmit ... 00022725W/

[Dod101]

This new healthcare company is interesting me quite a lot. And it is going to be quite some spin off because I saw a valuation somewhere the other day that values it at £45 billion and that is more than half the value of the entire Glaxo at the moment. Doing more than selling toothpaste then.

Dod

[Arborbridge]

This new healthcare company is interesting me quite a lot. And it is going to be quite some spin off because I saw a valuation somewhere the other day that values it at £45 billion and that is more than half the value of the entire Glaxo at the moment. Doing more than selling toothpaste then.

Dod

And Sir Dave has a good reputation. This might be one spin-off I retain rather than "rump selling" as I normally do.

Arb.

[Dod101]

This new healthcare company is interesting me quite a lot. And it is going to be quite some spin off because I saw a valuation somewhere the other day that values it at £45 billion and that is more than half the value of the entire Glaxo at the moment. Doing more than selling toothpaste then.

Dod

And Sir Dave has a good reputation. This might be one spin-off I retain rather than "rump selling" as I normally do.

Arb.

Yes and it is rather more than the 'rump' as some of these spin off's are.

Dod

[simoan]

This new healthcare company is interesting me quite a lot. And it is going to be quite some spin off because I saw a valuation somewhere the other day that values it at £45 billion and that is more than half the value of the entire Glaxo at the moment. Doing more than selling toothpaste then.

Dod

This does not surprise me and is why I started a thread specifically about the undervaluation of GSK on a sum of parts basis earlier this year: https://lemonfool.co.uk/viewtopic.php?f=33&t=27706

All the best, Si

[Dod101]

This new healthcare company is interesting me quite a lot. And it is going to be quite some spin off because I saw a valuation somewhere the other day that values it at £45 billion and that is more than half the value of the entire Glaxo at the moment. Doing more than selling toothpaste then.

Dod

This does not surprise me and is why I started a thread specifically about the undervaluation of GSK on a sum of parts basis earlier this year: https://lemonfool.co.uk/viewtopic.php?f=33&t=27706

All the best, Si

Sounds as if that was a good call but of course the value of a business and its share price can be very different but with the split it may be that investors will recognise that there is value there.

Dod

[BT63]

This does not surprise me and is why I started a thread specifically about the undervaluation of GSK on a sum of parts basis earlier this year: https://lemonfool.co.uk/viewtopic.php?f=33&t=27706

All the best, Si

I agree.
My scribblings on the back of an envelope suggest to me that the sum of the parts is at least 1.5x what the market is currently asking for the business.
GSK are currently my largest shareholding.

[idpickering]

US Govt buys additional 600,000 sotrovimab doses

GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

· 600,000 additional doses to be supplied to the US Government for distribution in Q1 2022, enabling further access to sotrovimab nationwide

· Brings total number of doses secured to date through binding agreements to approximately 1.7 million globally

· Preclinical data generated through both pseudo-virus and live virus testing demonstrate sotrovimab retains activity against all tested SARS-CoV-2 variants of concern including Delta and Omicron

https://www.investegate.co.uk/glaxosmit ... 08211013Y/

[vand]

Given that they rejected a £50bn bid for the soon to be spun-off company, and the current market cap of GSK is just £86bn... reaffirms that this company is worth a lot more than it currently trades for.

[nmdhqbc]

Given that they rejected a £50bn bid for the soon to be spun-off company, and the current market cap of GSK is just £86bn... reaffirms that this company is worth a lot more than it currently trades for.

is that £50bn for the GSK share of the spin-off or the whole thing? not sure what the pfizer % is of the company to work out how much of the £50bn would be associated with GSK's market cap if it is for the whole thing.

[Dod101]

The £50 billion offer is for the consumer goods division as a whole by my reading of the situation. Pfizer owns around 30% of it I think so that would give £35 billion or so to Glaxo. According to the Sunday Times, Unilever is likely to want to continue talks so watch this s pace.

Dod

[simoan]

The £50 billion offer is for the consumer goods division as a whole by my reading of the situation. Pfizer owns around 30% of it I think so that would give £35 billion or so to Glaxo. According to the Sunday Times, Unilever is likely to want to continue talks so watch this s pace.

Dod

I believe actual ownership is 32% for Pfizer. This bid could yet flush out other interested parties. I wouldn't rule out a combined PE bid. However, Johnson & Johnson have also stated they are selling their consumer business so there are other assets coming to market in the next 1-2 years. I wouldn't completely rule out Procter & Gamble either.

All the best, Si